Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

JHOP - June 2022 Vol 12, No 3 - FDA Oncology Update, Lymphoma, CAR T-Cell Therapy
Download PDF

On May 27, 2022, the FDA accelerated the approval of a new indication for the CD19-directed CAR T-cell therapy tisagenlecleucel (Kymriah; Novartis) for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication an orphan drug designation.

“The approval of Kymriah offers patients with relapsed or refractory follicular lymphoma a new treatment option and new hope for improving patient outcomes,” Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation, said in a press release. “Having this single infusion treatment option helps to transform the way healthcare providers approach this type of blood cancer.”

The approval was based on the ELARA study, a multicenter, single-arm, open-label clinical trial of adults with relapsed or refractory follicular lymphoma within 6 months after completion of ≥2 lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or relapsed after autologous hematopoietic stem-cell transplant.

The main efficacy measures were overall response rate (ORR) and duration of response (DOR). Among the 90 patients in the primary efficacy analysis, the ORR was 86% (95% confidence interval [CI], 77-92), including 68% complete responses. At 9 months, the median DOR was not reached, and 75% of those with a response were still responding to the CAR T-cell therapy. For the 98 patients who underwent leukapheresis, the ORR was 86% (95% CI, 77-92), including 67% complete responses.

The most common (>20%) adverse reactions were cytokine-release syndrome, infection, fatigue, musculoskeletal pain, headache, and diarrhea.

Continued approval for this indication may be contingent on verification of the clinical benefit in confirmatory trial(s).

Related Items
Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Rylaze Received FDA Approval of a New Dosing Regimen
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in FDA Oncology Update
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Copyright © The Lynx Group, LLC. All rights reserved.